Laser and radiofrequency ablations for benign and malignant thyroid tumors by G. Mauri et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=ihyt20
International Journal of Hyperthermia
ISSN: 0265-6736 (Print) 1464-5157 (Online) Journal homepage: https://www.tandfonline.com/loi/ihyt20
Laser and radiofrequency ablations for benign and
malignant thyroid tumors
Giovanni Mauri, Nicolò Gennaro, Min Kyoung Lee & Jung Hwan Baek
To cite this article: Giovanni Mauri, Nicolò Gennaro, Min Kyoung Lee & Jung Hwan Baek (2019)
Laser and radiofrequency ablations for benign and malignant thyroid tumors, International Journal
of Hyperthermia, 36:2, 13-20, DOI: 10.1080/02656736.2019.1622795
To link to this article:  https://doi.org/10.1080/02656736.2019.1622795
© 2019 The Author(s). Published with
license by Taylor & Francis Group, LLC
Published online: 20 Sep 2019.
Submit your article to this journal 
Article views: 951
View related articles 
View Crossmark data
Citing articles: 4 View citing articles 
Laser and radiofrequency ablations for benign and malignant thyroid tumors
Giovanni Mauria , Nicolo Gennarob , Min Kyoung Leec and Jung Hwan Baekc
aDivision of Interventional Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy; bTraining School in Radiology, Humanitas
University, Pieve Emanuele, Italy; cDepartment of Radiology and Research Institute of Radiology, Asan Medical Center, College of Medicine,
University of Ulsan, Songpa-gu, Seoul, Korea
ABSTRACT
A growing body of evidence is being published regarding the safety and efficacy of minimally invasive
image-guided ablation techniques. While clinical applications of these techniques are increasing, inter-
national societies have started to publish treatment guidelines and to make efforts to standardize
both terminology and reporting criteria for image-guided thyroid ablations. Laser ablation and radio-
frequency ablation (RFA) are among the most common ablation techniques either for benign and
malignant thyroid nodules. Unlike laser ablation and RFA in the treatment of benign thyroid nodules,
where safety and efficacy have been widely demonstrated, evidence regarding local tumor control of
thyroid malignancies is still limited. However, preliminary results are encouraging and image-guided
thermal ablation techniques can be considered a valid alternative to surgery for the treatment of
benign thyroid nodules and recurrent thyroid cancers. This review evaluates the basic concept of RFA
and laser ablations, their techniques, clinical outcomes, and complications based on the suggestions
of several society guidelines. Multidisciplinary collaboration remains critical to identify patients which
may benefit from minimally invasive image-guided thermal ablations, especially if surgery or radioio-
dine therapy are not feasible options.
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Introduction
Although most thyroid nodules are benign and treatment
is unnecessary, some of them require treatment because of
cosmetic reasons or subjective symptoms [1,2]. Surgery has
been the traditional treatment option for benign and
malignant thyroid tumors; however, it has several draw-
backs, such as scars, the need for general anesthesia, and
the risk of inducing hypothyroidism [3]. To overcome these
drawbacks, minimally invasive image-guided ablation tech-
niques such as ethanol ablation (EA), laser ablation, and
radiofrequency ablation (RFA) have been developed [3–5].
A growing body of evidence is being published regarding
their safety and efficacy. While clinical applications of these
techniques are increasing, ablation guidelines have been
published from Korean and Italian groups [3,6,7], and a
greater awareness has raised regarding standardization of
terminology and reporting criteria for image-guided thy-
roid ablations [8].
This review evaluates two widely used thermal ablation
methods, laser ablation and RFA. Based on the suggestions
of several society guidelines and currently available
evidences, we focus on basic concepts of percutaneous
thyroid ablations, techniques, clinical outcomes, and
complications.
Basic concept and techniques
Laser ablation
Laser (an acronym for ‘light amplification by stimulated emis-
sion of radiation’) is a highly coherent, collimated and mono-
chromatic energy that can be precisely delivered into small
targets from a primary source or through optical fibers that
allows a great variability in length and shape of applicators
[9]. Common primary sources are laser diode or neodymiu-
m–yttrium aluminum garnet, which produce optical wave-
lengths of 820 nm or 1064 nm. When laser light hits the
target, a local increase of temperature occurs, causing per-
manent damages such as coagulative necrosis (46–100 C)
and tissue carbonization/vaporization (100–110 C). The
grade and rapidity of tissue damage depend on many fac-
tors, including the amount of energy released, the applica-
tion time, the vascularization and the water content of the
tissue [10]. Laser ablation in the neck is usually performed
under ultrasound (US) guidance, which allows a real-time
monitoring of the procedure.
Before ablation, a comprehensive assessment of the target
lesion to treat is performed with US or contrast-enhanced US
(CEUS). The size and shape of the nodule, along with the
spatial relations with adjacent organs needs to be carefully
evaluated to avoid partial treatments or injury to
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surrounding organs. Local anesthesia is generally used, with
or without conscious sedation depending on patient anxiety
and operator preference. According to the size and shape of
the nodule, one or more 21 gauge needles are inserted
under real-time US guidance in the deepest portion of each
nodule. Up to four needles can be inserted simultaneously. A
distance of 1 cm should be ideally maintained between
inserted needles [4]. Then, a 300 mm diameter plane-cut
quartz optical fiber is inserted and advanced up to the intro-
ducer needle tip. The introducer needles are then pulled
back so as to expose the tip of each fiber at least 5mm in
direct contact with the target tissue [11]. Common protocols
are based on a mean power of 3–5W, for a total energy
delivery of 1200–1800 J for every illumination. After the first
illumination, the fiber(s) can be withdrawn by 1/1.5 cm and a
subsequent illumination can be performed (pull-back tech-
nique) until the whole target has been illuminated. Tissue
ablation can be monitored in real time following the enlarge-
ment of iper-echogenicity due to gas formation during treat-
ment. For benign nodules, the aim of the treatment is to
achieve a volume reduction of at least >50% [6,12], and a
variable amount of viable nodular tissue is generally main-
tained in the periphery of the nodule, also in order to reduce
the risk of possible complications. Conversely, for malignant
nodules, complete tissue destruction needs to be achieved.
Thus, laser ablation for malignant nodules requires a careful
assessment of the surrounding structure and an idoneous
localization of the nodule, ideally 5mm far from the thyroid
capsule. Hydrodissection can be performed to displace other
structures close to the tumor [10]. After the ablation, CEUS
can be performed to better identify the actual extent of the
ablation area, which can be generally overestimated by the
gas formed during ablation; a further ablation can be per-
formed during the same session in case CEUS demonstrate
untreated areas [13,14]. Laser ablation is generally performed
as an outpatient procedure that does not require particular
medication apart corticosteroids or analgesics in the rare
case of post-ablation pain.
Radiofrequency ablation
RFA uses an alternating electric current oscillating between
200 and 1200 kHz [15]. The radiofrequency electrode acts as
a cathode. The ions of targeting tumors adjacent to the elec-
trode tip vibrate rapidly in response to these alternating cur-
rents. This vibrating friction energy is transformed into heat,
while energy deposition drops exponentially away from the
tip. Tissue interaction with the temperature induced by
radiofrequency is similar to that of laser [15].
The revised 2017 thyroid RFA guidelines by Korean
Society of Thyroid Radiology suggest several standard techni-
ques [3]. For benign thyroid nodules, perithyroidal lidocaine
injection is recommended to control pain. The trans-isthmic
approach and moving-shot technique are essential for thy-
roid lesions. This technique is useful to minimize complica-
tions and marginal nodule regrowth. Recently, a novel
technique, named ‘vascular ablation technique’ has been
reported [16]. Two different vascular ablation techniques are
suggested: artery-first ablation and marginal venous ablation
(venous staining). These techniques have the potential to
enhance treatment efficacy and reduce the risk of regrowth.
For recurrent thyroid cancers, guidelines recommend careful
evaluation of critical structures before ablation, hydrodissec-
tion to reduce the risk of thermal damage to surrounding
critical structures, and the moving-shot technique.
Among possible complications, nerve damages are the
most serious and feared one during RFA [16]. Particularly,
voice change induced by thermal damage of recurrent laryn-
geal nerve is the most common complication related to
nerve damage. To lower the risk of damage, some technical
measures have been suggested. Recently, cold 5% dextrose
solution injection was introduced to treat nerve damage dur-
ing ablation [17]. If symptoms of nerve damage occur during
RFA, such as voice change, palpitations, Horner syndrome,
shoulder movement problems, or paresthesia, ablation
should be immediately stopped and a cold 5% dextrose solu-
tion is injected directly into the space in which the nerves
were located. In most patients, the cold fluids can treat
effectively the thermal damage of nerves [17].
Most operators performing thyroid RFA use a thyroid-
dedicated straight-type internally cooled electrode with short
shaft (7 cm) and small diameter (18–19 gauge) [16]. In small
recurrent thyroid cancers or parathyroid lesions, guidelines
recommend 19 gauge electrode tip (i.e. 3.8mm or 5mm
active tips). A recently introduced thyroid-dedicated bipolar
electrode has been introduced for pregnant women and for
patients carrying electrical devices (i.e. pacemaker) [16].
Benign thyroid nodule: outcomes and complications
Laser ablation
Laser ablation has been one of the first methods used to
perform image-guided ablation of benign thyroid nodules
and is nowadays considered among the recommended
techniques for the treatment of benign nodules [18]. A
randomized clinical study comparing laser ablation and
levothyroxine therapy reported a significant nodule volume
shrinkage after 1 year following laser ablation with a
negligible impact on thyroid function (TSH and FT4) [19].
Furthermore, laser ablation proved superior than TSH sup-
pression therapy regarding compression symptoms and vol-
ume reduction rate. Also in the long-term follow-up,
reduction of tumor volume proved stable over time after
laser ablation, with no need to reschedule additional ablative
sessions. Conversely, serial thermal ablations are indicated
for the treatment of large nodule (>20mm) [20,21].
Moreover, laser ablation possibly reduces the invasiveness of
the procedure due to its smaller energy applicators [10,22].
A recent meta-analysis of 19 papers and 2137 patients con-
firmed laser ablation to be safe and effective in reducing
benign thyroid nodules volume, improving thyroid function
and esthetic and ameliorating symptoms of compression,
especially for hypervascular nodules [23]. For the treatment
of benign thyroid nodule, outcomes of laser ablation seem
comparable to RFA, as also shown by a propensity score ana-
lysis [10,24].
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In 2003, Døssing et al. [25] reported the first case of a suc-
cessful US-guided laser ablation of an autonomous thyroid
nodule. Further studies confirmed that preliminary experi-
ence [26–29]. Reduction in tumor volume was achieved in a
large series of 82 patients with toxic nodular goiter-related
hyperthyroidism, especially in those patients with nodules
with a volume 15ml. Being all patients pretreated with
methimazole, all patients with an ablated goiter 5ml could
suspend medical therapy. For larger goiters, methimazole
discontinuation rate after the procedure depended on the
baseline goiter volume [30]. Laser ablation has been com-
pared to 131I radioiodine therapy for the treatment of hyper-
functioning benign nodules [23,26,28,30]. Despite a similar
reduction in nodule volume, normalization of serum TSH was
superior in the radioiodine groups, suggesting laser ablation
to be indicated only in the risk of radioiodine-induced hypo-
thyroidism or in pregnant women. Finally, combining laser
ablation with 131I therapy seems to induce a faster resolution
of systemic and local symptoms than 131I as single therapy.
This combined approach also allows to reduce the thera-
peutic dose of 131I administration [31,32]. Two cases of
laser ablation of a benign thyroid nodule are illustrated in
Figures 1 and 2.
RFA ablation
RFA reported excellent outcomes and low complication rates.
An initial large population single-center study with 236
patients reported 84.8% volume reduction at 1-year follow-
up [33]. Lim et al. reported 90% volume reduction rate at
and 94% at 1- and 4-year follow-up, with a 5.6% recurrence
rate. Moreover, patients’ symptoms and cosmetic issues were
improved after RFA [34]. A recent large multicenter prospect-
ive study performed by trained radiologists from multiple
institutions described a mean volume reduction at 12months
of 80.3%, increasing up to 95.3% after 5 years. Interestingly,
also symptoms and cosmetic scores showed significant
improvements [35].
When compared with surgery, RFA showed similar effi-
cacy, with the benefit of lower complication rates [36,37].
Similar to laser ablation, several papers discussed the role of
RFA for the treatment of autonomously functioning thyroid
nodules. Cesareo et al. [38] confirmed that RFA is effective in
achieving normalization of TSH levels in patients with small
autonomously functioning nodule (12ml), whose volume
shrinked up to 84% at 2-year follow-up compared to 68% in
nodules >12ml. These results confirmed the greater efficacy
of thermal ablation in small nodules, as also reported with
laser technique [30]. Bernardi et al. [39] and Baek et al. [40]
described as a single RFA restored euthyroidism in 45–50%
of patients with autonomously functioning benign thyroid
nodules, with mean a volume reduction of 75% after 1 year
from the procedure. A recent meta-analysis reported normal-
ization of TSH occurring in 57% patients and volume reduc-
tion up to 79% at 1-year follow-up, with a direct correlation
between baseline nodule volume and normalization of TSH
[38], as also observed after laser ablation [30]. A case of thy-
roid RFA is shown in Figure 3.
Complications
Complications of laser and RFA are similar in terms of inci-
dence and type [10]. They are rare and include transient dys-
phonia, local pain, hematoma, fever, skin infections and mild
burns. In a large retrospective series of thyroid laser abla-
tions, major complications occurred in 0.5% of cases (8
patients) and consisted of transient vocal cord palsy, which
completely recovered after 3months. Minor complications
were reported in 0.5% (9 patients) of cases, including sub-
capsular or perithyroidal hematoma and mild skin burn. Mild
pain was described as a side effect during the treatment
(10.6%) [21]. A large meta-analysis evaluating 2421 patients
with either benign and recurrent tumors treated with RFA
demonstrated overall complication rate to be 2.4–3.3%, with
a 1.4% major complication rate [16]. Only six patients (0.2%)
had persistent complication, including permanent voice
change, necessity for lobectomy due to abscess formation
and permanent hypothyroidism. Large population single-cen-
ter study [41] showed that the complication rate was higher
in recurrent tumors than benign ones (8.6% vs. 3.3%). Voice
change was most common and serious complication, caused
either by lidocaine injection, nerve compression due to
hematoma, local inflammation or perineural fibrosis [42];
however, permanent damage (dysphonia or vocal cord palsy)
is extremely rare [17], and most patients recovered without
special treatment within 3months [43]. Despite the rarity of
permanent voice changes, a higher risk exists for patients
with recurrent thyroid cancer [41]. Other reported complica-
tions are exceedingly rare and include Horner syndrome, bra-
chial plexus nerve injury, transient thyrotoxicosis or
hypothyroidism [43]. The application of standard techniques,
a deep knowledge of the anatomy of the neck and prompt
management of nerve damage is required to minimize
complications.
Malignant thyroid nodule: outcomes and
complications
Laser ablation
Laser ablation can be applied in the treatment of primary
thyroid tumors or in recurrent tumors that are not suitable
for surgery [4,29]. Moreover, laser ablation has been also pro-
posed as alternative to active surveillance or surgery in the
treatment of papillary microcarcinoma [4,44–48]. Even
though evidences regarding the outcome of laser ablation
are still limited compared to the benign pathology, good
clinical results have been reported for tumor debulking and
temporary improvement of mass-related symptoms [29]. Up
to 10 years ago, the body literature of laser ablation for the
treatment of malignant thyroid nodules was substantially
limited to case reports and small case series [9,47,48]. In the
meanwhile, its feasibility and efficacy have been demon-
strated in ex-vivo models and in larger clinical series [49].
Zhang et al. [50] described clinical outcomes of 64 cases of
papillary thyroid microcarcinomas treated with laser ablation,
reporting only two incomplete ablations that were detected
by CEUS performed immediately after the procedure. US-
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guided fine-needle aspiration at 1, 6, and 12months after
treatment did not show residual tumors, with no regrowth of
treated lesions detected during a mean follow-up of
26months. Successful tumor control in metastatic lymph
node in the neck from papillary thyroid carcinomas have
been reported by Papini et al. in a small series of five
patients who experienced a mean volume reduction was
64% and 88% at 6 and 12months, respectively. Moreover, no
regrowth along with normalization of serum Tireoglobulin on
LT4 was registered [51]. Similarly, Mauri et al. [13] described
a larger series of patients experiencing successful local tumor
control in 73% of cases at 6months and 71.4% of cases at
12months. All patients had previously undergone surgery
and radioiodine ablation, and were at high risk of re-inter-
vention, with a negative radioiodine scan. Authors obtained
technical success in all cases with no major complications
and reported a local tumor control in 86.9% of cases over a
follow-up of 30months and no residual disease on imaging
in 79.1% of cases. Local control was achieved in 71.4% of
cases at 1 year. Laser ablation has been used successfully for
the treatment of local recurrence of papillary cancer in a
cohort of 21 patients, which underwent 18 single ablative
sessions and 3 repeated treatments due to viable tumor
areas detected at CEUS [52]. A recent paper by Ji et al.
reported successful outcome in 37 patients diagnosed with
papillary microcarcinoma. After a gradual volume increase
due to tissue edema within the first 3months, at 24-month
follow-up tumor volume decrease from a mean of 5.5mm to
1.1mm, 32.4% primary lesions completely disappeared, and
64.9% remained as cicatricial hyperplasia. Only one patient
had cervical lymph node and underwent open surgery [53].
These results are very similar to the outcomes described by
Zhou et al. few years before [54], thus confirming percutan-
eous laser ablation to be safe and effective for the treatment
of single papillary thyroid microcarcinoma.
RFA ablation
RFA achieved excellent results for treating recurrent thyroid
cancers [55]. Current thyroid RFA guideline suggested two
treatment strategies, being cure or palliative treatment [3].
Cure is defined as treatment of all visible tumors on US. In
Figure 1. (a) US representation of a benign thyroid nodule. (b) Two laser applicators have been introduced within the nodule, with a distance of 5mm between
the needle tips. (c) Gas bubbles in the nodule are the immediate effect of thermal ablation. (d) Immediate post-procedural CEUS shows lack of contrast enhance-
ment in the central part of the nodule. (e) Six-month follow-up shows volumetric reduction of the ablated nodule. (f) CEUS of the ablated nodule shows shrinkage
and low vascularization of the inner core of the nodule, due to cicatricial effects.
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terms of outcomes, a meta-analysis found that recurrent
tumors were completely disappeared in 69% patients, with a
71.6% serum thyroglobulin reduction rate [55]. Recent long-
term follow-up study (mean follow-up, 80 months) reported
91.3% completely ablated tumors that completely disap-
peared during follow-up, together with a significant decrease
of serum thyroglobulin level; however, four new recurrent
tumors and two distant metastases were detected during the
follow-up period [56]. Meta-analysis comparing RFA and EA
demonstrated RFA to be superior in terms of efficacy and to
require fewer treatment sessions, even if EA showed lower
complication rates [55]. Several studies compared the efficacy
and safety of RFA with those of surgery using a propensity
score analysis [57,58]. The results showed that recurrence-
free survival was similar in both groups, but RFA showed low
complication rates than surgery. RFA also achieved good
results in primary thyroid cancers, especially microcarcinoma
(T1N0M0) [59]. Zhang et al. [60] reported a prospective study
for treating microcarcinoma using RFA. The mean volume
tumor reduction ratio was 96% at 1 year and complete tumor
disappearance was 10.2%. No local tumor recurrence or
metastasis to lymph nodes in the neck was observed during
the short follow-up period (7.8months). Kim et al. [61]
reported in a 4-year follow-up study mean volume reduction
rate of 98.5% and complete disappearance rate of 66.7%,
with no local tumor recurrence or lymph nodes metastases
Figure 2. (a,b) US representation of a benign thyroid nodule. (b) Two laser applicators have been introduced within the nodule, with a distance of 5mm
between the needle tips (arrows). (c,d) Two needles are introduced in the nodule and gently moved during the procedure according to the pull-back technique
(dotted arrows). (e) Air bubbles (arrows) within the ablated nodule (black arrowheads). (f) Post-procedural CEUS confirms lack of contrast enhancement inside the
ablated nodule (white arrowheads).
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in the neck. RFA was tolerated in all patients with primary
thyroid carcinoma without major complications or proced-
ure-related deaths [62].
Conclusion
Image-guided thermal ablations such as laser ablation and
RFA are well-established minimally invasive procedures
that can be considered valid alternatives to surgery in the
treatment of benign thyroid nodules. In patients with thyroid
malignancies, evidences are still limited but results in terms
of local tumor control are promising. Multidisciplinary collab-
oration is critical to identify thermal ablation as a treatment
option in patient where surgery and radioiodine therapy are
not feasible. To maximize clinical outcomes and minimize
complications, operators should be properly trained, master
the anatomy of the neck and apply standard techniques rec-
ommended by current guidelines.
Figure 3. (a) US representation of a benign thyroid nodule (6.4 4.0 2.8 cm) in the left thyroid lobe. (b) Prominent vascularization is confirmed at Doppler US.
(c) RF applicator with 1 cm size active tip is introduced within the nodule (arrow). (d) Post-procedural US shows decreased vascularization in nodule and air bubbles
as hyperechoic areas (arrows). (e) After 1month, the size of nodule is decreased (2.2 3.7 4.5 cm). (f) Further dimensional reduction after
1 year (1.3 1.4 2.4 cm).
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